TY - JOUR
T1 - Ileoanal pouch-related fistulae
T2 - A systematic review with meta-analysis on incidence, treatment options and outcomes
AU - Pellino, Gianluca
AU - Celentano, Valerio
AU - Vinci, Danilo
AU - Romano, Francesco Maria
AU - Pedone, Agnese
AU - Vigorita, Vincenzo
AU - Signoriello, Giuseppe
AU - Selvaggi, Francesco
AU - Sciaudone, Guido
N1 - Copyright © 2022. Published by Elsevier Ltd.
PY - 2023/3
Y1 - 2023/3
N2 - Background: Ileoanal pouch related fistulae (PRF) are a complication of restorative proctocolectomy often requiring repeated surgical interventions and with a high risk of long-term recurrence and pouch failure. Aims: To assess the incidence of PRF and to report on the outcomes of available surgical treatments. Methods: A PRISMA-compliant systematic literature search for articles reporting on PRF in patients with inflammatory bowel diseases (IBD) or familial adenomatous polyposis (FAP) from 1985 to 2020. Results: 34 studies comprising 770 patients with PRF after ileal-pouch anal anastomosis (IPAA) were included. Incidence of PRF was 1.5-12%. In IBD patients Crohn's Disease (CD) was responsible for one every four pouch-vaginal fistulae (PVF) (OR 24.7; p=0.001). The overall fistula recurrence was 49.4%; procedure-specific recurrence was: repeat IPAA (OR 42.1; GRADE +); transvaginal repair (OR 52.3; GRADE ++) and transanal ileal pouch advancement flap (OR 56.9; GRADE ++). The overall failure rate was 19%: pouch excision (OR 0.20; GRADE ++); persistence of diverting stoma (OR 0.13; GRADE +) and persistent fistula (OR 0.18; GRADE +). Conclusion: PVFs are more frequent compared to other types of PRF and are often associated to CD; surgical treatment has a risk of 50% recurrence. Repeat IPAA is the best surgical approach with a 42.1% recurrence rate.
AB - Background: Ileoanal pouch related fistulae (PRF) are a complication of restorative proctocolectomy often requiring repeated surgical interventions and with a high risk of long-term recurrence and pouch failure. Aims: To assess the incidence of PRF and to report on the outcomes of available surgical treatments. Methods: A PRISMA-compliant systematic literature search for articles reporting on PRF in patients with inflammatory bowel diseases (IBD) or familial adenomatous polyposis (FAP) from 1985 to 2020. Results: 34 studies comprising 770 patients with PRF after ileal-pouch anal anastomosis (IPAA) were included. Incidence of PRF was 1.5-12%. In IBD patients Crohn's Disease (CD) was responsible for one every four pouch-vaginal fistulae (PVF) (OR 24.7; p=0.001). The overall fistula recurrence was 49.4%; procedure-specific recurrence was: repeat IPAA (OR 42.1; GRADE +); transvaginal repair (OR 52.3; GRADE ++) and transanal ileal pouch advancement flap (OR 56.9; GRADE ++). The overall failure rate was 19%: pouch excision (OR 0.20; GRADE ++); persistence of diverting stoma (OR 0.13; GRADE +) and persistent fistula (OR 0.18; GRADE +). Conclusion: PVFs are more frequent compared to other types of PRF and are often associated to CD; surgical treatment has a risk of 50% recurrence. Repeat IPAA is the best surgical approach with a 42.1% recurrence rate.
KW - Restorative proctocolectomy
KW - Treatment of ileal pouch fistula
KW - Treatment of pouch-vaginal fistula
KW - Colonic Pouches
KW - Anastomosis, Surgical/adverse effects
KW - Humans
KW - Treatment Outcome
KW - Neoplasm Recurrence, Local/surgery
KW - Incidence
KW - Postoperative Complications/surgery
KW - Crohn Disease/complications
KW - Female
KW - Fistula/complications
KW - Colitis, Ulcerative/complications
KW - Proctocolectomy, Restorative/adverse effects
UR - http://www.scopus.com/inward/record.url?scp=85131839337&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/7913e8e8-497e-3cf6-94d8-da5f6a9eb679/
UR - https://portalrecerca.uab.cat/en/publications/adaa73ea-da4b-4545-9898-4eb2a694cf05
U2 - 10.1016/j.dld.2022.05.009
DO - 10.1016/j.dld.2022.05.009
M3 - Review article
C2 - 35688686
AN - SCOPUS:85131839337
SN - 1590-8658
VL - 55
SP - 342
EP - 349
JO - Digestive and Liver Disease
JF - Digestive and Liver Disease
IS - 3
ER -